---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-318435"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T14:35:58.741145+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q3 net loss $6.6M; cash $312.8M post-$198.7M IPO

## Summary
- Cash and equivalents $312.8M as of Sep 30, 2021, up from $15.2M at Dec 31, 2020.
- Net loss of $6.6M ($0.72/sh) for Q3 2021 vs $2.3M ($1.47/sh) in Q3 2020.
- Nominated TYRA-200 (FGFR2 inhibitor) for clinical development; IND expected 2H 2022.
- Appointed Esther van den Boom CFO, John Healy GC, Allison Kemner VP, Rehan Verjee to board.
- R&D expenses $5.5M (up from $1.9M) driven by pipeline advancement and personnel costs.

## SEC filing metadata
- accession: 0001193125-21-318435
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312521318435/0001193125-21-318435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312521318435/d223896d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-318435
- JSON: https://secwatch.observer/filing/0001193125-21-318435.json
- Plain text: https://secwatch.observer/filing/0001193125-21-318435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.